MVC quadrivalent flu vaccine received the NDA approval letter from Taiwan FDA, and will invest in the domestic quadrivalent flu vaccine supply.
MVC cooperates with GC Pharma, a large Korean pharmaceutical company. GC Pharma produces the vaccine bulk, and then MVC conducts fill-and-finish, sub-packaging and quality control release. MVC quadrivalent flu vaccine is suitable for the adults and children aged 3 years and older to prevent influenza caused by two influenza A subtype viruses and two types of B viruses. The latest quadrivalent flu vaccine will be provided according to the changes of the virus strains announced by the WHO each year. MVC will invest in the quadrivalent flu vaccine market in Taiwan and bring new choices of high-quality vaccines to the government and the public.